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Introduction
The recent research paper by the Milan group reports the
time to recurrence after removal of a primary breast tumour
in a group of 1173 patients entered into clinical trials in
Milan between 1964 and 1980 [1]. All patients were
treated by radical or modified radical mastectomy but they
did not receive postoperative radiotherapy or chemo-
therapy. Previous analyses of this patient series estimating
the hazard ratio for relapse at 6–12 month intervals reported
peaks of relapse at 18 months and 60 months and then a
tapered plateau like tail of relapse extending up to 15 years
[2]. The early peak was more pronounced in patients with
node-positive tumours that were more than 2 cm in
diameter. No differences in the curves were seen for local
and distant relapse or for pre- and postmenopausal
patients. At the same time Saphner and colleagues
reported similar findings [3], with the additional observation
that the early peak was significantly higher in oestrogen
receptor (ER) negative tumours. No ER data are available
for the Milan series.
In the current paper by the Milan group, the aim of the
authors was to further interrogate the kinetics of the first
peak. Hazard rates were calculated at three month
intervals and the authors report in detail 368 patients with
a local (95) or distant (273) relapse within the first four
years after surgery. The analysis demonstrates, for the first
time, a double peak of early relapse with maximum at
8–10 months and 28–30 months for premenopausal
patients, but a wide peak with a maximum at
18–24 months for postmenopausal patients. When divided
into node-positive and node-negative, the double pattern
was seen only in node-positive premenopausal patients: it
was more pronounced in patients with more than three
nodes involved, but was unrelated to tumour size.
This analysis therefore confirms a previous one in the
same group of patients, which showed that 27% of all
distant relapses of premenopausal node-positive patients
occurred within the first ten months, if not treated with
adjuvant therapy [4]. The first question to ask is whether
the differences between pre- and postmenopausal
patients are real. The authors did not assess the
differences between the curves statistically, but by eye
there does appear to be a definite early peak in the
premenopausal group. Given the relatively small numbers
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Abstract
There is great interest among oncologists concerning what we might learn by examining the pattern of
relapse after breast cancer surgery. What you see depends upon how hard you look. Up to now,
investigators have examined the hazard ratio for relapse every 6–12 months. In a research paper,
published in this issue of Breast Cancer Research, the Milan group have looked at the hazard ratio every
three months and have found, for the first time, a distinct, very early peak of relapse in a group of
premenopausal, node-positive patients not given chemotherapy or hormone therapy. What is now needed
is for other groups to repeat this observation and, if found, to examine the characteristics of the tumours
producing this phenomenon in order to develop hypotheses about its cause and possible treatments.
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of patients involved, the analysis needs repeating in another
large series. An early peak was not seen in the Saphner
series but the hazard ratios were only examined annually.
Why is there an early peak of recurrence?
If we assume there is a peak of recurrence at
8–10 months we have to explain why there is a peak at all,
why so soon after surgery and why only in premenopausal
women. There was no break down of the data to tell us
whether the phenomenon was associated with younger or
older premenopausal women. This would be of interest
because of the particularly poor prognosis of very young
breast cancer patients.
The authors’ explanation for the early peak of recurrence is
that surgery triggers the release of micrometastases from
a dormant state either by stimulating the release of
angiogenic factors or inhibiting angiogenic inhibitors. In
previous publications they have also hypothesised that
growth factors released during the wounding of surgery
may also stimulate tumour growth [5]. It is important to
emphasise the great heterogeneity of breast tumours and
the variability in times of relapse. Tumours that relapse
after some years tend to be steroid hormone receptor
(HR) positive whereas those that relapse early tend to be
HR negative and HER1/HER2 positive. In late relapses
micrometastases may well be dormant for months or years
and then begin to grow. This is best seen in local relapse
where clinical examination may find nothing on several
occasions, and on the next examination a small mass is
found (or more often, detected by the patient) [6]. This
suggests dormancy followed by growth. Whether growth
is initiated by an acquired ability of tumour cells to induce
angiogenesis is not clear, but this is a widely held
hypothesis. Micrometastases in axillary lymph nodes have
few blood vessels, whereas larger nodal metastases are
well vascularised suggesting that there may be an
angiogenetic switch [7]. However, in animal models where
tumour cells are injected into, for example, the portal
system, single cells can be found in the liver many months
afterwards. These cells can form tumours when they are
removed from the liver and injected into mammary fat
pads; therefore the liver environment must be keeping the
cells dormant in some way [8]. This is unlikely to be
related to angiogenesis since the tumour cells are angio-
genic when transferred to the fat pad, and recent
evidence suggests that metastatic breast tumours can use
existing blood vessels in the liver [9].
At the other end of the heterogeneity scale are tumours
that relapse early (the subject of the recent research
paper). Although we do not have any histological or
immunochemical details of the tumours used by the Milan
group, data from other studies indicate that the tumours
are likely to be not only HR negative and HER1/2 positive,
but also high grade, with high microvessel density and
vascular invasion [10–12]. The fact that lymph node
metastases are often large and vascularised at diagnosis
in these cases indicates that we need not necessarily
involve an angiogenic switch (as the authors suggest)
since at the time of surgery not only the primary tumour,
but also detectable metastases are well vascularised. Nor
need we necessarily invoke dormancy, since this group of
tumours have already shown their ability to grow and
vascularise in axillary lymph nodes before operation. The
early peak could simply represent a subgroup of tumours
with similar growth characteristics uninterrupted by
surgery. It is of interest that tumour cells can be detected
in peripheral blood two to three weeks after surgery in
poor prognosis groups, as this suggests release from
existing subclinical metastases [12].
Angiogenesis inhibition
The hypothesis that the primary tumour somehow affects
the growth of metastases is compelling. Large numbers of
animal experiments show that removal of the primary
tumour is associated with increased proliferation of
smaller tumours, whether they are metastases or small
inoculae of the same tumour type. Holmgren and
colleagues [13] subcutaneously inoculated mice with
Lewis lung carcinoma or the T241 sarcoma and showed
that dormant micrometastases developed in the lungs. The
inoculae were removed when they reached a volume of
1.5–2.0 cm, which triggered the growth of the lung
micrometastases. It was further shown that treatment of
the mice with an angiogenesis inhibitor (TNP-470)
prevented the growth of lung metastases suggesting that
release from dormancy is via an angiogenic switch.
However, Fisher and colleagues [14] demonstrated that
increased growth of small transplanted tumours in one
flank, after removal of a large ‘primary’ tumour in the other,
was associated with factors in serum that could not only
stimulate tumour growth in vivo in other animals, but also
of the same tumour cells in vitro. The latter experiment
suggests that the factor or factors were not angiogenic.
Proliferative factors were present in the serum within
hours of the operation, but wounding did not appear to
explain this result, since a sham operation (removal of the
hind limb) did not result in tumour growth.
Aside from Fisher’s experiment, other data support the
wounding hypothesis. Recently, Tagliabue and colleagues
demonstrated that removal of part of a primary human
mammary tumour resulted in increased growth rates of
residual primary tumour (incomplete excision) but only in
tumours that were HER-2 positive. Wound drainage fluid
and post surgical serum samples stimulated growth of
HER-2 over-expressing cells, which were abolished by
trastuzumabab [15]. These experiments are important
because measurements were made on fluids from
wounds, which may not be reflected in blood
measurements. Hombrey and colleagues [16]257
demonstrate very high concentrations of vascular
endothelial growth factor (VEGF) in wound fluid but small
changes in peripheral blood VEGF levels after surgery for
breast cancer. It is possible that the early peak of relapse
is seen only in premenopausal women because the breast
is primed to produce proliferative factors by high
endogenous steroid hormones.
Conclusions
The data outlined above suggest that the explanation for
the peak of relapse seen at 8–10 months in the Milan
series is related to a group of tumours that other studies
suggest are inherently highly vascularised and metastatic.
The presence of lymph node metastases at diagnosis
suggests the capacity for angiogenesis is present in the
cells, and there are probably metastases in other sites
which are also quite large, given the finding of tumour
cells in the peripheral blood after a period of two to three
weeks. Whether there is an increased growth of
metastases at the time of surgery, either due to growth
stimulators or removal of inhibitors produced by the
tumour or by wounding, is suggested by the peak of
relapse, but this remains to be clearly demonstrated in
humans. The limited experimental data we have indicates a
need for further clinical studies to define the potential
regulators involved. There is also a need to assess
whether treatment across the surgical period with HER1/2
inhibitors, for example, will help improve the outcome of
patients with poor prognosis tumours that do not respond
well to conventional therapies.
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